Pinned Tweet
Here at @RadOncUH we train our residents to become the trailblazers for tomorrow’s standard of care.
@lauren_henke @angela_jia_
Full video here: youtu.be/hfAxfEtflk0?si=hFze…
RadOncUH retweeted
Proud to be on Luke’s cheer squad today as he rang the bell for @Browns #CrucialCatch for cancer screening. Luke’s a ⭐️, bravely sharing his story of young-onset colorectal cancer. Get screened, & if you have symptoms, get tested ASAP. It might save your life. 💙 GO BROWNS! 🧡
RadOncUH retweeted
Amazing trip to Prague for @ESTRO_RT ’s workshop on direct-to-unit (née sim-free) RT. Got to watch @APrice_BeamOn lecture as faculty & represent our creative @RadOncUH team & collaborators, see many dear friends, & join in as ad-hoc guest physician faculty on a topic I love!
RadOncUH retweeted
Make that THREE papers this week! 🚨
RAPTOR is out: 3,120 men & 11 RCTs. After RT alone, being BCR-free at 5y marked a functional-cure benchmark (8y DM 6.6%; 10y PCSM 2.5%). W/ ADT, late metastatic risk persisted.
doi.org/10.1016/j.euo.2026.0… @AmarUKishan @DrSpratticus @alison_tree
Two papers in a week! 🚨
Now out in @IJROBP: after testosterone recovery following RT+ADT, faster PSA kinetics were associated w/ progression but the relationship with metastatic risk was inconsistent. redjournal.org/article/S0360…
Just days after our NADIR validation in ARCHES! 🔬
RadOncUH retweeted
Two papers in a week! 🚨
Now out in @IJROBP: after testosterone recovery following RT+ADT, faster PSA kinetics were associated w/ progression but the relationship with metastatic risk was inconsistent. redjournal.org/article/S0360…
Just days after our NADIR validation in ARCHES! 🔬
Thrilled to share our ARCHES external validation of NADIR, now in Cancer!
In 558 men with mAPMS on enzalutamide, NADIR showed AUC 0.80 w/ strong calibration for predicting PSA ≤0.2 by 6 months.
acsjournals.onlinelibrary.wi…
@neerajaiims @DrRanaMcKay @AarmstrongDuke @DrSpratticus
RadOncUH retweeted
Another @RadOncUH PGY-4 with an 🎤🔥oral presentation today! @SamLM_MD killing it presenting the ✅feasibility of planning on HyperSight CBCT on TrueBeam in a prospective trial- @SiemensHealth Varian CMO @DrDee2014 & physics PI @APrice_BeamOn both front row, cheering him on!
NCT05975619
RadOncUH retweeted
@RadOncUH PGY-4 @QingLi_MDPhD 🔥crushing it with an(other) 🎤oral presentation this morning on her #HolmanPathway work on how RT modulates HER2 expression and trastuzuman deruxtecan response in HER2 low metastatic breast cancer.
#bcsm @TyMillerLab
RadOncUH retweeted
@ASTRO_org #ASTRO26 trial data ➡️how we approach 🧠mets from SCLC has officially, fundamentally changed.
🤔Want to know how to put @SWOG MAVERICK & @NRGonc CC009 together?
🎧Listen to our @NRGonc podcast about BOTH trials with Chad Rusthoven!
👉🏼 tinyurl.com/muhkda7t
#btsm
RadOncUH retweeted
Loving being @S_W_R_O’s event with some of the very incredible women in rad onc that I look up to very much, and am inspired by on the daily. Amazing way to close out the day at @ASTRO_org #ASTRO26. Super thrilled to have @luliacevedo joining @RadOncUH faculty for H&N, too 🎉❤️
RadOncUH retweeted
Congratulations @luliacevedo on another successful event and your job!!!
RadOncUH retweeted
incredible turnout, so much fun meeting everyone, the future is bright!
Full house at our @RadOncUH #ASTRO2026 Meet & Greet! 🎯☢️
So much fun meeting the next generation of #RadOnc and introducing them to our residents and faculty. Thanks to everyone who came out—we may have taken over Flight Club just a little 💙
RadOncUH retweeted
Expert and thoughtful discussion by the indomitable #JaniceLyons (not to mention fabulous colleague @RadOncUH ). Findings right in line with relevant elements of SKAGEN 1, HypoG-01, and Fast-Forward Nodal sub-study findings. But does one size fit all? Some words of caution for T4 disease, under represented here 🚩, and in those with residual modal disease after NAC. 🚩
RadOncUH retweeted
#ASTRO26
Awesome catching up with @alison_tree @angela_jia_ @HimanshuNagarMD and @RadOncUH former resident @RohanPatelMD who is faculty at MCW with @whallradonc
All of them continue to inspire me!
RadOncUH retweeted
So great to see residents excited about trials! The room was packed!
Even better if they have excellent mentors like @lauren_henke @angela_jia_
The future is bright!
#ASTRO26 @ASTRO_org
RadOncUH retweeted
#ASTRO26
@KashaniRojano the Vice Chair and Director of Physics and Dosimetry @RadOncUH giving a masterclass education session on motion management @ASTRO_org
@APrice_BeamOn @lauren_henke @angela_jia_ @PranshuMohindra @Soum_Roy_RadOnc @HaleyPerlow
RadOncUH retweeted
New #ASTRO2026 data from @NRGOnc /RTOG 0534 SPPORT 🔬🧬 presented by Shuang (George) Zhao @UTMDAnderson. PAM50 Luminal B = both prognostic & predictive of benefit from postop ADT.
📈 5-y FFP benefit: 31% vs 10% (p-int=.01)
🎯 10-y MFS: 20% vs -3% (p-int=.05)
#Pcsm @Astro_org
RadOncUH retweeted
1/5 🧵 @NRGOnc GU003 5-y: HYPORT 62.5 Gy/25 fx increased G3 GU toxicity vs conventional RT (13% vs 3%) ⚠️, with no improvement in biochemical control.
BUT!!! Before we conclude hypofractionation is worse, take heed—this is a DOSE ESCALATION problem.
RadOncUH retweeted
Want more detail?
🎧Listen to our episode of the @NRGonc podcast recorded with George and @StephenChunMD as soon as the clinical trials session closes
👉🏼podcasts.apple.com/us/podcas…
👉🏼 open.spotify.com/show/6ai8U7…
@ASTRO_org #ASTRO26
New #ASTRO2026 data from @NRGOnc /RTOG 0534 SPPORT 🔬🧬 presented by Shuang (George) Zhao @UTMDAnderson. PAM50 Luminal B = both prognostic & predictive of benefit from postop ADT.
📈 5-y FFP benefit: 31% vs 10% (p-int=.01)
🎯 10-y MFS: 20% vs -3% (p-int=.05)
#Pcsm @Astro_org